What is the name of the study which investigated dasatinib vs imatinib in treatment naive CML patients?

The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) study was a randomized phase III trial comparing the efficacy and safety of dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP).

How does dasatinib differ from imatinib?

Dasatinib is 325 times as potent as imatinib in inhibiting unmutated BCR-ABL kinase in vitro. Since increased inhibition of BCR-ABL kinase correlates with a better clinical response,18 administration of dasatinib as the initial therapy may improve responses in patients with newly diagnosed chronic-phase CML.

What is imatinib made of?

Imatinib, a 2-phenyl amino pyrimidine derivative, is a tyrosine kinase inhibitor with activity against ABL, BCR-ABL, PDGFRA, and c-KIT. The active sites of tyrosine kinases each have a binding site for ATP.

Is SPRYCEL better than Gleevec?

NEW YORK (Reuters) – Bristol-Myers Squibb’s cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers reported on Saturday.

How is CML 2020 treated?

Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP).

Is CML curable?

A stem cell or bone marrow transplant is the only potential cure for CML, but it’s a very intensive treatment and is not suitable for many people with the condition.

What are the side effects of dasatinib?

Dasatinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

• muscle pain.
• weakness.
• joint pain.
• pain, burning or tingling in the hands or the feet.
• rash.
• skin redness.
• peeling skin.
• swelling, redness, and pain inside the mouth.

What are the side effects of imatinib?

Side Effects Upset stomach, nausea/vomiting, diarrhea, headache, muscle/joint pain, muscle cramps, dizziness, blurred vision, or drowsiness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Is imatinib a cure?

Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib.

Is imatinib a chemo drug?

Imatinib (Gleevec®) is a Chemotherapy Regimen for Chronic Myeloid Leukemia (CML)

What is the best drug for CML?

The standard treatment for chronic phase CML is a tyrosine kinase inhibitor (TKI) like imatinib (Gleevec), nilotinib (Tasigna), dasatinib (Sprycel), or bosutinib (Bosulif). If the first drug stops working or it never really worked well at all, the dose may be increased or another TKI might be tried.

Can CML be cured?

What was the outcome of the dasatinib versus Imatinib study?

The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) study was a randomized phase III trial comparing the efficacy and safety of dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP).

What was the outcome of the dasision trial?

DASISION was a multinational, open-label, phase III trial (CA180-056; ClinicalTrials.gov identifier: NCT00481247). Patients were stratified by Euro risk score 19 and randomly assigned 1:1 to receive either oral dasatinib (100 mg once daily) or imatinib (400 mg once daily).

What are the results of the 5 year dasision study?

We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib.

How long does it take to get rid of dasatinib?

For the present analysis, all patients had a minimum follow-up of 12 months. The median dose of dasatinib that was delivered was 99 mg per day (range, 21 to 136), and the median dose of imatinib delivered was 400 mg per day (range, 125 to 657). The median duration of treatment was 14.0 months (range,…